Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study
Background: The chronic myeloid leukaemia population, treatment patterns and responses in Portugal are unknown. The aim of this study is to describe these features in a Portuguese reference centre. Methods: A retrospective cohort study included patients with chronic myeloid leukaemia, treated betwee...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137925002032 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839637925907660800 |
|---|---|
| author | Ana Maria Meireles Rita Calisto Maria José Bento Pedro Martinho Gouveia Susana Bizarro Manuel Teixeira Cláudia Moreira Ana Espírito Santo Mário Mariz |
| author_facet | Ana Maria Meireles Rita Calisto Maria José Bento Pedro Martinho Gouveia Susana Bizarro Manuel Teixeira Cláudia Moreira Ana Espírito Santo Mário Mariz |
| author_sort | Ana Maria Meireles |
| collection | DOAJ |
| description | Background: The chronic myeloid leukaemia population, treatment patterns and responses in Portugal are unknown. The aim of this study is to describe these features in a Portuguese reference centre. Methods: A retrospective cohort study included patients with chronic myeloid leukaemia, treated between 2012 and 2022 at the Instituto Português de Oncologia of Porto. Data were obtained from the Cancer Registry of the institution and clinical records. Variables included demographic data, treatments administered, responses (hematologic, cytogenetic, major and deep molecular responses), adverse events, and survival. Patients without available data, those treated in a clinical trial context, and those admitted only for hematopoietic transplantation were excluded. Results: Ninety-nine patients were included in this study, with a median age of 52 years (range: 7–84 years) at diagnosis. The first-line treatment was imatinib in 96 patients however 33 required second-line with dasatinib, and 17 discontinued treatment while maintaining response. Regarding responses, 95 (96 %) patients achieved cytogenetic response, 90 (94 %) achieved major molecular response, and 71 (72 %) achieved deep molecular response. At three months, the early molecular response rate was 77 %. At 12 months of treatment, of the 67 patients with response evaluation, 93 % achieved complete cytogenetic response and 49 % major molecular response. Both imatinib and dasatinib were well tolerated. The median follow-up was eight years. The five-year overall survival was 96 %. Conclusion: This study is the first to characterize chronic myeloid leukaemia patients at a Portuguese centre. The patient characteristics, responses, and overall survival were within the expected range according to the literature. This study confirms the good prognosis of chronic myeloid leukaemia and the good responses using imatinib as first-line treatment. |
| format | Article |
| id | doaj-art-a0ae163f07624f83b5ca7d4fab434a16 |
| institution | Matheson Library |
| issn | 2531-1379 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj-art-a0ae163f07624f83b5ca7d4fab434a162025-07-06T04:23:39ZengElsevierHematology, Transfusion and Cell Therapy2531-13792025-07-01473103935Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational studyAna Maria Meireles0Rita Calisto1Maria José Bento2Pedro Martinho Gouveia3Susana Bizarro4Manuel Teixeira5Cláudia Moreira6Ana Espírito Santo7Mário Mariz8Department of Hematology and Bone Marrow Transplantation, Instituto Português de Oncologia do Porto (IPO Porto), Porto, Portugal; Clinical Oncology Group, IPO Porto Research Center (CI-IPOP), Instituto Português de Oncologia do Porto (IPO Porto), Porto, Portugal; Group of Epidemiology, Results, Economy and Management in Oncology – Research Center, Porto Comprehensive Cancer Center (Porto. CCC) & RISE@CI-IPOP (Health Research Network), Porto, Portugal; Corresponding author. Ana Maria Meireles, Instituto Português de Oncologia do Porto, Rua Dr. António Bernardino de Almeida 865, 4200-072 Porto, Portugal.Group of Epidemiology, Results, Economy and Management in Oncology – Research Center, Porto Comprehensive Cancer Center (Porto. CCC) & RISE@CI-IPOP (Health Research Network), Porto, Portugal; Population Studies Department. School of Medicine and Biomedical Sciences, ICBAS, University of Porto, Portugal Epidemiology Service, Instituto Português de Oncologia do Porto (IPO Porto), Porto, PortugalGroup of Epidemiology, Results, Economy and Management in Oncology – Research Center, Porto Comprehensive Cancer Center (Porto. CCC) & RISE@CI-IPOP (Health Research Network), Porto, Portugal; Population Studies Department. School of Medicine and Biomedical Sciences, ICBAS, University of Porto, Portugal Epidemiology Service, Instituto Português de Oncologia do Porto (IPO Porto), Porto, PortugalUnidade Local de Saúde Santo António, Porto, PortugalOncogenetics Group, IPO Porto Research Center (CI-IPOP), Instituto Português de Oncologia do Porto (IPO Porto), Porto, Portugal; Instituto Português de Oncologia do Porto (IPO Porto), Porto, PortugalOncogenetics Group, IPO Porto Research Center (CI-IPOP), Instituto Português de Oncologia do Porto (IPO Porto), Porto, Portugal; Instituto Português de Oncologia do Porto (IPO Porto), Porto, PortugalDepartment of Hematology and Bone Marrow Transplantation, Instituto Português de Oncologia do Porto (IPO Porto), Porto, Portugal; Clinical Oncology Group, IPO Porto Research Center (CI-IPOP), Instituto Português de Oncologia do Porto (IPO Porto), Porto, Portugal; Group of Epidemiology, Results, Economy and Management in Oncology – Research Center, Porto Comprehensive Cancer Center (Porto. CCC) & RISE@CI-IPOP (Health Research Network), Porto, PortugalDepartment of Hematology and Bone Marrow Transplantation, Instituto Português de Oncologia do Porto (IPO Porto), Porto, Portugal; Clinical Oncology Group, IPO Porto Research Center (CI-IPOP), Instituto Português de Oncologia do Porto (IPO Porto), Porto, Portugal; Group of Epidemiology, Results, Economy and Management in Oncology – Research Center, Porto Comprehensive Cancer Center (Porto. CCC) & RISE@CI-IPOP (Health Research Network), Porto, PortugalDepartment of Hematology and Bone Marrow Transplantation, Instituto Português de Oncologia do Porto (IPO Porto), Porto, Portugal; Group of Epidemiology, Results, Economy and Management in Oncology – Research Center, Porto Comprehensive Cancer Center (Porto. CCC) & RISE@CI-IPOP (Health Research Network), Porto, PortugalBackground: The chronic myeloid leukaemia population, treatment patterns and responses in Portugal are unknown. The aim of this study is to describe these features in a Portuguese reference centre. Methods: A retrospective cohort study included patients with chronic myeloid leukaemia, treated between 2012 and 2022 at the Instituto Português de Oncologia of Porto. Data were obtained from the Cancer Registry of the institution and clinical records. Variables included demographic data, treatments administered, responses (hematologic, cytogenetic, major and deep molecular responses), adverse events, and survival. Patients without available data, those treated in a clinical trial context, and those admitted only for hematopoietic transplantation were excluded. Results: Ninety-nine patients were included in this study, with a median age of 52 years (range: 7–84 years) at diagnosis. The first-line treatment was imatinib in 96 patients however 33 required second-line with dasatinib, and 17 discontinued treatment while maintaining response. Regarding responses, 95 (96 %) patients achieved cytogenetic response, 90 (94 %) achieved major molecular response, and 71 (72 %) achieved deep molecular response. At three months, the early molecular response rate was 77 %. At 12 months of treatment, of the 67 patients with response evaluation, 93 % achieved complete cytogenetic response and 49 % major molecular response. Both imatinib and dasatinib were well tolerated. The median follow-up was eight years. The five-year overall survival was 96 %. Conclusion: This study is the first to characterize chronic myeloid leukaemia patients at a Portuguese centre. The patient characteristics, responses, and overall survival were within the expected range according to the literature. This study confirms the good prognosis of chronic myeloid leukaemia and the good responses using imatinib as first-line treatment.http://www.sciencedirect.com/science/article/pii/S2531137925002032Chronic myelogenous leukaemia BCR-ABL positiveImatinib mesylateTyrosine kinase inhibitorsEpidemiologyMyeloproliferative disorders |
| spellingShingle | Ana Maria Meireles Rita Calisto Maria José Bento Pedro Martinho Gouveia Susana Bizarro Manuel Teixeira Cláudia Moreira Ana Espírito Santo Mário Mariz Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study Hematology, Transfusion and Cell Therapy Chronic myelogenous leukaemia BCR-ABL positive Imatinib mesylate Tyrosine kinase inhibitors Epidemiology Myeloproliferative disorders |
| title | Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study |
| title_full | Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study |
| title_fullStr | Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study |
| title_full_unstemmed | Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study |
| title_short | Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study |
| title_sort | epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre a retrospective observational study |
| topic | Chronic myelogenous leukaemia BCR-ABL positive Imatinib mesylate Tyrosine kinase inhibitors Epidemiology Myeloproliferative disorders |
| url | http://www.sciencedirect.com/science/article/pii/S2531137925002032 |
| work_keys_str_mv | AT anamariameireles epidemiologicalcharacterizationofchronicmyeloidleukaemiapatientsatanoncologiccentrearetrospectiveobservationalstudy AT ritacalisto epidemiologicalcharacterizationofchronicmyeloidleukaemiapatientsatanoncologiccentrearetrospectiveobservationalstudy AT mariajosebento epidemiologicalcharacterizationofchronicmyeloidleukaemiapatientsatanoncologiccentrearetrospectiveobservationalstudy AT pedromartinhogouveia epidemiologicalcharacterizationofchronicmyeloidleukaemiapatientsatanoncologiccentrearetrospectiveobservationalstudy AT susanabizarro epidemiologicalcharacterizationofchronicmyeloidleukaemiapatientsatanoncologiccentrearetrospectiveobservationalstudy AT manuelteixeira epidemiologicalcharacterizationofchronicmyeloidleukaemiapatientsatanoncologiccentrearetrospectiveobservationalstudy AT claudiamoreira epidemiologicalcharacterizationofchronicmyeloidleukaemiapatientsatanoncologiccentrearetrospectiveobservationalstudy AT anaespiritosanto epidemiologicalcharacterizationofchronicmyeloidleukaemiapatientsatanoncologiccentrearetrospectiveobservationalstudy AT mariomariz epidemiologicalcharacterizationofchronicmyeloidleukaemiapatientsatanoncologiccentrearetrospectiveobservationalstudy |